Decoding EG.5.1: The UK-Associated Omicron Sub-Variant Found in India - Insights and Precautions
In a manner akin to a relentless factory, the Omicron variant of COVID-19 has been generating a series of sub-variants since its emergence in 2022. Its latest creation, known as EG.5.1 or 'Eris', has already made its presence felt in over 45 countries, including India.
Recent revelations unveiled the rapid propagation of a fresh Omicron XBB sub-strain in the UK. This sub-variant is accountable for one out of every seven COVID-19 cases within the nation, constituting nearly 15% of the total cases. As a result, it stands as the second most prevalent COVID strain in the UK.
The pace of transmission exhibited by EG.5.1 is estimated to be around 45% swifter than XBB.1.16, the Arcturus subvariant that emerged earlier this year.
Moreover, the World Health Organization's (WHO) latest weekly epidemiological report highlighted an ascending trend in EG.5.1's prevalence. Consequently, in July, the agency elevated this sub-variant's status to the list of monitored variants.
Despite the swift dissemination of EG.5.1, experts have reassured that the trajectory of infections attributed to this sub-variant doesn't warrant alarm.
A puzzling aspect emerges: EG.5.1 was actually identified in India several months ago!
Dr. Rajesh Karyakarte, the coordinator for genome sequencing in Maharashtra and a senior scientist at Pune's BJ Medical College, disclosed that EG.5.1 was detected in Maharashtra as early as May.
However, despite its presence, there hasn't been a notable surge in COVID cases in India during June and July. Curiously, the sub-variant seems to have failed to make a substantial impact in the country. Instead, XBB.1.16 and XBB.2.3 continue to maintain their dominance.
Concurrently, healthcare facilities in various regions of India have reported an increase in patients presenting flu-like symptoms recently. While viral infections during the monsoon season are not uncommon, these symptoms shouldn't be casually disregarded.
Experts advise staying vigilant for any potential signs of COVID-19 and consulting with healthcare professionals accordingly. Much like Omicron, the typical symptoms of EG.5.1 encompass a runny nose, headache, fatigue (mild or severe), sneezing, and sore throat.
In the ongoing battle against COVID-19, adhering to safety protocols such as wearing masks in public spaces and frequent hand sanitization remains strongly advisable.